BACKGROUND

Post-traumatic stress disorder (PTSD) is a complex and difficult-to-treat psychiatric condition with high unmet need.

It is characterized by re-experiencing, avoidance, and hyperarousal.

Mostly female (61%), majority White (71%), mixed trauma.

With a diagnosis of PTSD with a CAPS-5 Total score ≥30 and PCL-5 score ≥38.

This exploratory study was the first study of NYX-783 in patients with PTSD.

The study compared NYX-783 50 mg QD (n=26) vs placebo (n=38).

RESULTS: EFFICACY

The preplanned combined analysis of stages 1 and 2 provided a numerical benefit for the CAPS-5 Total score, CAPS-5 Cluster scores, and HADS Anxiety score. After baseline imbalances in time since trauma were corrected, improvement was significant (exploratory).

CONCLUSIONS

NYX-783 demonstrated positive results across the following areas:

- Numerical improvement was observed.
- Significant improvements were observed, improvement was significant (exploratory).
- Significant improvements demonstrated clinically reliable change (≥13 points).
- There were no discontinuations due to adverse events.

REFERENCES